Guest Editors
Rahul Kalhapure, PhD, University of KwaZulu-Natal, South Africa
Zhiwen Luo, MD, PhD, Fudan University, China
Chun-Wai Mai, PhD, RPh, IMU University, Malaysia
Dr Kalhapure is an Honorary Associate Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal (UKZN), South Africa. He earned his PhD from the Institute of Chemical Technology in India. Currently, he serves as a Principal Scientist at Odin Pharmaceuticals in the USA, overseeing the development of sterile complex dosage forms. Previously, he worked at the University of Texas at El Paso, USA. From 2013 to 2017, he held the position of NRF Scientist at UKZN. His research focuses on dendrimers, novel biocompatible materials, and nano-drug delivery. Dr Kalhapure holds three granted US Patents and has authored over 60 scientific publications in peer-reviewed journals. He also serves as an Editorial Board member for "Drug Delivery Letters" and is a member of the Topical Advisory Panel for "Pharmaceutics".
Dr Luo holds a PhD jointly conferred in biomaterials from the National University of Singapore and in miRNA mechanisms from the Shanghai Institute for Nutrition and Health, Chinese Academy of Sciences. Currently, he serves as the Director Assistant at the Fudan University Institute of Sports Medicine in China, providing research guidance to multiple institutions and holding accreditation as an expert for China’s National Medical Products Administration. He is a Full Member of both the Sigma Xi Scientific Research Honor Society (USA) and the Chinese Anti-Cancer Association. Dr Luo also holds editorial roles in 30 academic journals, serves as a reviewer for over 50 SCI journals, and has guest-edited for more than 10 SCI journals. He has authored over 50 papers in SCI-indexed journals, with 41 as the first, co-first, or corresponding author.
Dr Mai currently serves as a Professor at the Institute for Research, Development and Innovation, IMU University (Malaysia). He has been the Head of Pharmaceutical Chemistry at the Faculty of Pharmaceutical Sciences, UCSI University. His academic journey also includes completing a postdoctoral certificate from Shanghai Jiao Tong University, China. With over a decade of dedicated focus on cancer research, Dr Mai possesses extensive expertise in this field. He has received prestigious awards, including the FIP Early Career in Pharmaceutical Science Award (2023) and the Rising Star Award from the Malaysia Association for Cancer Research (2019). Employing a pioneering cell-cell interaction model both in vitro and in vivo, Dr Mai investigates novel approaches to combat these challenges. Leveraging state-of-the-art, disease-relevant phenotypic, and target-based assays, He aims to decipher the mechanisms of action of various compounds to enhance cancer patients' prognosis and treatment outcomes.Bombyx mori silk is one of the most extensively studied types of silk due to its unique mechanical properties and biocompatibility, which have enabled its Utilization in medical applications Including surgical su...
Citation:
¾Á¸»ŠÊ˜·³Ç Biotechnology
2025
25:38
